Plasma amyloid-β forms in Alzheimer's disease and Non-Alzheimer's disease patients

Journal of Alzheimer's Disease

Volumn 21, Issue 1, 2010, Pages 291-301

  Le Bastard, Nathalie ^a   Leurs, Judith ^b   Blomme, Walter ^b   De Deyn, Peter Paul ^a,c,d   Engelborghs, Sebastiaan ^a,c,d,e  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b Esoterix Inc   (United States)

^c MIDDELHEIM HOSPITAL   (Belgium)

^d Artesis University   (Belgium)

^e UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Alzheimer's disease; amyloid; biomarkers; non Alzheimer's disease dementia; plasma

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ISOPROTEIN; PEPTIDE FRAGMENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DEMENTIA; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; AREA UNDER THE CURVE; BLOOD; COMPARATIVE STUDY; MENTAL HEALTH; PROCEDURES; STATISTICS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AREA UNDER CURVE; DEMENTIA; FEMALE; HUMANS; IMMUNOASSAY; MALE; MENTAL STATUS SCHEDULE; PEPTIDE FRAGMENTS; PROTEIN ISOFORMS; STATISTICS AS TOPIC;

EID: 77954979947     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-091501     Document Type: Article

References (44)

1. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C (1992) Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359, 325-327.
2. Hardy J and Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
3. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13, 45-53.
4. Sergeant N, Bombois S, Ghestem A, Drobecq H, Kostanjevec-ki V, Missiaen C, Wattez A, David JP, Vanmechelen E, Sergher-aert C, Delacourte A (2003) Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. JNeurochem 85, 1581-1591.
5. Larner AJ (1999) Hypothesis: amyloid beta-peptides truncated at the N-terminus contribute to the pathogenesis of Alzheimer's disease. Neurobiol Aging 20, 65-69.
6. Liao MQ, Tzeng YJ, Chang LY, Huang HB, Lin TH, Chyan CL, Chen YC (2007) The correlation between neurotoxici-ty, aggregative ability and secondary structure studied by sequence truncated Abeta peptides. FEBSLett 581, 1161-1165.
7. Kumar-Singh S, De Jonghe C, Cruts M, Kleinert R, Wang R, Mercken M, De SB, Vanderstichele H, Lofgren A, Vander-hoeven I, Backhovens H, Vanmechelen E, Kroisel PM, van BC (2000) Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease. Hum Mol Genet 9, 2589-2598.
8. Andreasen N and Blennow K (2005) CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neu-rolNeurosurg 107, 165-173.
9. Sonnen JA, Montine KS, Quinn JF, Kaye JA, Breitner JC, Montine TJ (2008) Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol 7, 704-714.
10. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wis-niewski HM (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57, 100-105.
11. Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, Eikenberg O, Antz C, Krause WR, Reulbach U, Kornhuber J, Wiltfang J (2004) Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging 25, 273-281.
12. Pijnenburg YA, Schoonenboom SN, Mehta PD, Mehta SP, Mulder C, Veerhuis R, Blankenstein MA, Scheltens P (2007) Decreased cerebrospinal fluid amyloid beta (1-40) levels in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 78, 735-737.
13. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC (2003) Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 60, 958-964.
14. Sobow T, Flirski M, Kloszewska I, Liberski PP (2005) Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta Neurobiol Exp (Wars) 65, 117-124.
15. Tamaoka A, Fukushima T, Sawamura N, Ishikawa K, Oguni E, Komatsuzaki Y, Shoji S (1996) Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci 141, 65-68.
16. Giedraitis V, Sundelof J, Irizarry MC, Garevik N, Hyman BT, Wahlund LO, Ingelsson M, Lannfelt L (2007) The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neur osci Lett 427, 127-131.
17. Roher AE, Esh CL, Kokjohn TA, Castano EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo YM, Emmerling MR, Soares H, Quinn JF, Kaye J, Connor DJ, Silverberg NB, Adler CH, Seward JD, Beach TG, Sabbagh MN (2009) Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement 5, 18-29.
18. Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, Mehta PD (2003) Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61, 1185-1190.
19. Mayeux R, Tang MX, Jacobs DM, Manly J, Bell K, Merchant C, Small SA, Stern Y, Wisniewski HM, Mehta PD (1999) Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol 46, 412-416.
20. Pesaresi M, Lovati C, Bertora P, Mailland E, Galimberti D, Scarpini E, Quadri P, Forloni G, Mariani C (2006) Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 27, 904-905. (Pubitemid 44287903)
21. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM (2006) Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 5, 655-660.
22. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K (2008) Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 31, 215-223.
23. Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H, Van Everbroeck B, Cras P, Martin JJ, Vanmechelen E, De Deyn PP (2008) Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 29, 1143-1159.
24. Engelborghs S, Dermaut B, Goeman J, Saerens J, Marien P, Pickut BA, Van den Broeck M, Serneels S, Cruts M, Van Broeckhoven C, De Deyn PP (2003) Prospective Belgian study ofneurodegenerative and vascular dementia: APOE genotype effects. J Neurol Neurosurg Psychiatry 74, 1148-1151.
25. Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, De Leenheir E, Martin JJ, Vanmechelen E, Van Broeck-hoven C, De Deyn PP (2007) No association ofCSF biomark-ers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. Brain 130, 2320-2326.
26. Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, Wolf S, Otto M, Reulbach U, Kolsch H, Jessen F, Schroder J, Schonknecht P, Hampel H, Peters O, Weimer E, Perneczky R, Jahn H, Luckhaus C, Lamla U, Sup-prian T, Maler JM, Wiltfang J (2008) Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: amulticenter study. Neurobiol Aging 29, 812-818.
27. Olsson A, Vanderstichele H, Andreasen N, De MG, Wallin A, Holmberg B, Rosengren L, Vanmechelen E, Blennow K (2005) Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 51, 336-345.
28. Vanderstichele H, De Meyer G, Andreasen N, Kostanjevecki V, Wallin A, Olsson A, Blennow K, Vanmechelen E (2005) Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clin Chem 51, 1650-1660.
29. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group (1998) Consensus report of the Working Group on: Molecular and Biochemical Markers of Alzheimer's Disease. Neurobiol Aging 19, 109-116.
30. Lachno DR, Vanderstichele H, De GG, Kostanjevecki V, De MG, Siemers ER, Willey MB, Bourdage JS, Konrad RJ, Dean RA (2009) The influence of matrix type, diurnal rhythm and sample collection and processing on the measurement ofplas-ma beta-amyloid isoforms using the INNO-BIA plasma abeta forms multiplex assay. JNutr Health Aging 13, 220-225.
31. Lambert JC, Schraen-Maschke S, Richard F, Fievet N, RouaudBerr C, Dartigues JF, Tzourio C, Alperovitch A, Buee L, Amouyel P (2009) Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study. Neurology 73, 847-853.
32. Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser E, Maier W, Jessen F, Burger K, Hampel H, Frolich L, Henn F, Falkai P, Ruther E, Jahn H, Luckhaus C, Perneczky R, Schmidtke K, Schroder J, Kessler H, Pantel J, Gertz HJ, Vanderstichele H, De MG, Shapiro F, Wolf S, Bibl M, Wiltfang J (2010) Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. Exp Neurol 223, 366-370.
33. Andreasen N, Sjogren M, Blennow K (2003) CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42. World J Biol Psychiatry 4, 147-155.
34. Le Bastard N, Martin JJ, Vanmechelen E, Vanderstichele H, De Deyn PP, Engelborghs S (2009) Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiol Aging, in press.
35. Pomara N, Doraiswamy PM, Willoughby LM, Roth AE, Mul-sant BH, Sidtis JJ, Mehta PD, Reynolds CF, III, Pollock BG (2006) Elevation in plasma Abeta42 in geriatric depression: a pilot study. Neurochem Res 31, 341-349.
36. Sun X, Steffens DC, Au R, Folstein M, Summergrad P, Yee J, Rosenberg I, Mwamburi DM, Qiu WQ (2008) Amyloid-associated depression: a prodromal depression of Alzheimer disease? Arch Gen Psychiatry 65, 542-550.
37. Qiu WQ, Sun X, Selkoe DJ, Mwamburi DM, Huang T, Bhadela R, Bergethon P, Scott TM, Summergrad P, Wang L, Rosenberg I, Folstein M (2007) Depression is associated with low plasma Abeta42 independently of cardiovascular disease in the homebound elderly. Int J Geriatr Psychiatry 22, 536-542.
38. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, Dekosky ST (2001) Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee ofthe American Academy of Neurology. Neurology 56, 1133-1142.
39. Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194.
40. Boustani M, Peterson B, Hanson L, Harris R, Lohr KN (2003) Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 138, 927-937.
41. Sundelof J, Giedraitis V, Irizarry MC, Sundstrom J, Ingelsson E, Ronnemaa E, Arnlov J, Gunnarsson MD, Hyman BT, Basun H, Ingelsson M, Lannfelt L, Kilander L (2008) Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol 65, 256-263.
42. Lopez OL, Kuller LH, Mehta PD, Becker JT, Gach HM, Sweet RA, Chang YF, Tracy R, Dekosky ST (2008) Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 70, 1664-1671.
43. Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R (2008) Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci USA 105, 14052-14057.
44. Blennow K, De Meyer G., Hansson O, Minthon L, Wallin A, Zetterberg H, Lewczuk P, Vanderstichele H, Vanmechelen E, Kornhuber J, Wiltfang J (2009) Evolution of Abeta42 and Abeta40 Levels and Abeta42/Abeta40 Ratio in Plasma during Progression of Alzheimer's Disease: A Multicenter Assessment. JNutr Health Aging 13, 205-208.